What we're thankful for at FierceBiotech

Over the course of the past 8 weeks, we've been registering some big gains in reader traffic here at FierceBiotech. Every day, our life sciences reports are opened and read more than 75,000 times in biotech hubs around the world. Our stories drew 1.6 million page views last month alone. And a fresh lineup of special reports has continued to drive a rapid expansion of our audience. So we have a lot to be thankful for. In particular, I'm thankful that you spend part of every work day at Fierce, dear reader. In a world in which so many things clamor for attention on the Web, your time is a lot to ask for, and we never take it for granted.

As we always do this time of year, we're taking a break for the holidays. We'll be off on Thursday for Thanksgiving and then back on Friday with our annual look at the most popular FierceBiotech stories and special reports on the Web this year. I hope you can take a moment to check in with us to see what topped the online charts. And of course we'll be back in full force on Monday with a fresh slate of reports from our news center. For our U.S. readers, enjoy the holidays. For everyone else around the world who reads us--and it's a big group--please indulge us the national holiday here. -- John Carroll, Editor-in-Chief. Follow me on Twitter and LinkedIn.


Suggested Articles

The FDA sent Eton's partner, Bausch Health, a complete response letter that raised “no concerns” about the clinical data in the drug’s application.

A new partnership will test drug cocktails containing Karyopharm's new product Xpovio in cell samples from glioblastoma patients.

Boehringer signed a deal to buy out a small immuno-oncology player this morning, and AbbVie’s been at it, too, inking a deal to snap up Mavupharma.